Details for Patent: 12,226,406

Which drugs does patent 12,226,406 protect, and when does it expire?

Patent 12,226,406 protects QINLOCK and is included in one NDA.

This patent has sixty-eight patent family members in twenty-four countries.

Summary for Patent: 12,226,406

Title:	Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Abstract:	Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof.
Inventor(s):	Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Assignee:	Deciphera Pharmaceuticals LLC
Application Number:	US18/795,711
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 12,226,406

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes			Y

International Family Members for US Patent 12,226,406

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	122354
Argentina	122355
Australia	2020417282
Australia	2020419197